Botulinum toxin type A was first used for the treatment of spasticity in 1989. A small uncontrolled study of treatment of upper limb spasticity after stroke reported encouraging benefits, including ...

— Achieved key co-primary endpoint on efficacy, with 500U dose demonstrating statistically significant difference from placebo in the Modified Ashworth Score (MAS) improvement from baseline — ...

VANCOUVER -- Guidelines for the use of botulinum toxin in various neurological disorders are getting an update, with the best evidence supporting the use of some formulations in spasticity and chronic ...

The American Academy of Neurology has updated its 2008 guidelines on the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm and migraine headache, based on recent research. The ...

In the United States, someone has a stroke every 40 seconds.[i] Though stroke death rates have declined in recent decades, it is a leading cause of serious long-term disability,[ii] taking a toll on ...

Spasticity is a disabling complication of stroke, and it is uncertain whether intramuscular injections of botulinum toxin type A reduce disability in persons with spasticity of the wrist and fingers ...

RESEARCH TRIANGLE PARK – Merz Therapeutics, with North American headquarters in Raleigh, has gained a new use for Xeomin, its botulinum toxin therapy. The U.S. Food and Drug Administration approved ...

Botulinum toxin therapy has emerged as a pivotal treatment in the management of spasticity, a debilitating neuromuscular condition characterised by increased muscle tone and hyperactive reflexes. By ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced an ...

Botulinum toxin is an established treatment for upper limb spasticity after stroke and it should be delivered to meet agreed rehabilitation goals. [6] Randomized controlled trials evaluating the use ...